NCT02777008

Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CTP-543 in Healthy Subjects

A Two-Part Single Center, Randomized, Sequential, Single and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CTP-543 in Healthy Volunteers

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 77 (actual)
• Sponsor: Concert Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years – 50 Years
• Healthy volunteers: Accepted

Summary

Single- and multiple-ascending dose study of CTP-543 in healthy volunteers.

Detailed description

This two-part study will assess, in healthy volunteers, under fasted conditions, and in a sequential manner, the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single- and multiple-ascending doses of CTP-543.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	CTP-543
DRUG	Placebo for CTP-543

Timeline

• Start date: 2016-05-01
• Primary completion: 2016-12-01
• Completion: 2017-03-01
• First posted: 2016-05-19
• Last updated: 2017-03-13

Locations

1 site across 1 country: Australia